Central nervous system medical device company Mensia Technologies has been awarded approximately U.S. $3.9 million to develop an original, noninvasive therapeutic medical device for children with ADHD.
The grant — part of the H2020/SME Instrument call for projects — will help in the development of Mensia’s Newrofeed device. Based on neurofeedback training of the brain, Newrofeed is used at home under medical supervision to identify and quantify abnormal brain activity in ADHD patients in real time. It also personalizes treatment with a care protocol adapted to each child and retrains the patient’s brainwave pattern for lasting normalization.
Mensia CEO Jean-Yves Quentel says the company will launch a clinical study of the device in 2016 to demonstrate its efficacy. — Michael Cipriano